Grants & Programs

Partnerships

Clinical Accelerator is jointly managed by the Cancer Research Institute and Ludwig Cancer Research, two leading cancer research nonprofit organizations committed to driving innovation in the field of immuno-oncology.

Cancer Research Institute
  • Public nonprofit organization established in 1953 dedicated exclusively to advancing research in cancer immunology and development of cancer immunotherapies
  • ~$30 million in research grants per year with over $280 million invested since inception
  • In 2010, established a nonprofit venture capital fund to make investments in priority clinical trials in partnership with leading biopharma companies
Ludwig Cancer Research
  • International nonprofit foundation established in 1971 committed to integrated laboratory and clinical discovery to improve the understanding and control of cancer
  • More than $1.5 billion invested in cancer research to date
  • Sophisticated ability to sponsor and conduct clinical trials to translate Ludwig discoveries
  • >40 ongoing product development programs based on IP or technologies from Ludwig

 

Biotech and Pharmaceutical Company Partnerships

Cancer Research Institute and Ludwig Cancer Research partner with leading biopharma companies to access priority drugs for inclusion in our clinical studies. These partners represent the best of what’s new in the field of immuno-oncology, and through our work with them, our network of researchers are able to access more than 30 of the most promising new treatments for clinical study.

  • CureVac

    CureVac

    CRI, Ludwig Cancer Research, and CureVac, a biopharmaceutical company, announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatments.

    The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf
    The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf
    The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. - See more at: http://cancerresearch.org/news/2013/november/curevac-collaborates-with-cancer-research-institute-and-ludwig-to-enable-clinical-testing-of-cancer-immunotherapies#sthash.UBPibWEn.dpuf

  • GITR, Inc.

    CRI and Ludwig have invested in and are managing a phase I trial of the first anti-GITR antibody to be tested in humans.

  • Immune Design

    Immune Design

    CRI and Ludwig will focus on clinical testing novel combinations of two investigational immunotherapies from Immune Design's pipeline.

  • MedImmune

    MedImmune

    CRI and Ludwig have partnered with MedImmune, the global biologics arm of AstraZeneca, to investigate novel uses of three top immuno-modulatory antibodies in CVC clinical trials.

  • Oncovir, Inc.

    CRI and Ludwig have invested to support the manufacture of a significant batch of a promising immune adjuvant for inclusion in CVC trials.

  • VentiRx Pharmaceuticals

    VentiRx

    CRI and Ludwig will focus on VentiRx's motolimod (VTX-2337), a Toll-like receptor 8 agonist, for clinical testing of novel combinations.

Other Nonprofit Partnerships

Because immunotherapy is a platform technology with application to myriad types of cancer, CRI seeks out partnerships with leading indication-specific cancer nonprofits. Through these invaluable partnerships, CRI is able to tap into leading scientific experts for specific types of cancer and secure valuable co-funding for its network’s most promising immunotherapy clinical trial ideas for a particular type of cancer.

Become a Partner

Interested in working with the Clinical Accelerator on your immunomodulator drug? Contact Adam Kolom at akolom@cancerresearch.org.